newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

  • MapLight Therapeutics announced that the FDA granted Fast Track designation to ML-007C-MA for treating hallucinations & delusions associated with Alzheimer's disease psychosis (ADP).
  • Fast Track designation facilitates development & review for serious conditions with unmet needs, allowing for frequent FDA interactions, accelerated approval, & priority review if criteria are met.
  • Chief Medical Officer Erin Foff stated the designation highlights the significant unmet need for ADP treatments & recognizes the program's potential to address psychotic symptoms accompanying cognitive decline.
  • The company is currently enrolling 300 participants in the Phase 2 VISTA study, a randomized, double-blind, placebo-controlled trial, with top-line results expected in the second half of 2027.
  • Previous Phase 1 trials demonstrated a favorable safety & tolerability profile for ML-007C-MA with twice-daily dosing in healthy elderly participants.
  • ML-007C-MA is an oral, extended-release, fixed-dose combination of the M1/M4 muscarinic agonist ML-007 & a peripherally acting anticholinergic (PAC) designed to activate CNS receptors while mitigating peripheral side effects.
  • ADP affects approximately 40% of individuals with Alzheimer's disease, leading to faster cognitive decline, higher institutionalization rates, & increased mortality.
  • MapLight Therapeutics is a clinical-stage biopharmaceutical company founded to address the lack of circuit-specific pharmacotherapies for central nervous system disorders.